The SOPHiA DDM™ Platform will help broaden the
hospital's cancer testing and diagnostic capabilities
BOSTON and ROLLE, Switzerland, May 16, 2024
/PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native
software company and a leader in data-driven medicine, today
announced that Klinikum Klagenfurt am Wörthersee, the third largest
hospital in Austria, is live on
the SOPHiA DDM™ Platform. The hospital will use SOPHiA GENETICS'
technology to enhance its next-generation sequencing (NGS) testing
and deepen its analytical capabilities for solid tumor and blood
cancer (hematology oncology) samples.
Klinikum Klagenfurt am Wörthersee is home to one of the largest
laboratories in Austria, the
Institute for Laboratory Diagnostics and Microbiology (ILM), which
provides comprehensive laboratory tests and services. The ILM
services the hospital's more than half a million patients annually,
as well as patients at neighboring hospitals throughout the state
of Carinthia. The ILM, as well as the Insitute of Clinical
Pathology and Molecular Pathology, offer a wide range of routine
and special analyses for many disease areas, including both solid
tumor cancers and blood cancers. With the SOPHiA DDM™ Platform,
clinicians at Klinikum Klagenfurt am Wörthersee can ensure fast and
accurate genomic analysis to better equip providers to make
data-driven treatment decisions.
"Precision medicine makes novel therapies for cancer treatment
possible," said Kevin Puylaert, Managing Director, EMEA, SOPHiA
GENETICS. "The implementation of the SOPHiA DDM™ Platform will help
Klinikum Klagenfurt am Wörthersee produce reliable insights from
its testing while saving time and valuable resources."
"As one of the largest laboratories in Austria, the volume of data we have to analyze
is immense. Using the SOPHiA DDM™ Platform, we can expand our
molecular diagnostics and provide clinicians findings faster," said
Dr. Sabine Sussitz-Rack, Head of the ILM, Klinikum Klagenfurt am
Wörthersee.
Dr. Martin Hyden, Senior Doctor
at Institute of Clinical Pathology and Molecular Pathology, added
"Our ability to run samples through the SOPHiA DDM™ Platform's
NGS-based workflows will help our clinicians quickly obtain
biologically actionable insights from each sample to support
data-driven decision-making."
The SOPHiA DDM™ Platform uses next-generation sequencing to
target key variants from FFPE, blood, or bone marrow samples
helping lead to better detection of variants associated with the
disease. The Platform is specifically designed to compute a wide
array of genomic variants and continually hone machine learning
algorithms.
With the SOPHiA DDM™ Platform, Klinikum Klagenfurt am Wörthersee
will retain complete ownership of its database, supporting its
clinical and research team as it continues to increase its
expertise and build upon its learnings.
For more information on SOPHiA GENETICS, visit
SOPHiAGENETICS.COM, or connect on LinkedIn.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare
technology company on a mission to expand access to data-driven
medicine by using AI to deliver world-class care to patients with
cancer and rare disorders across the globe. It is the creator of
the SOPHiA DDM™ Platform, which analyzes complex genomic and
multimodal data and generates real-time, actionable insights for a
broad global network of hospital, laboratory, and biopharma
institutions. For more information, visit SOPHiAGENETICS.COM
and connect with us on LinkedIn.
SOPHiA DDM™ Dx Myeloid is available as a CE-IVD product
for In Vitro Diagnostic Use in Europe and Turkey. SOPHiA DDM™ Custom Solid
Tumor Solutions are for Research Use Only and not for use in
diagnostic procedures, unless specified
otherwise. The information in this press release
is about products that may or may not be available in different
countries and, if applicable, may or may not have received approval
or market clearance by a governmental regulatory body for different
indications for use. Please contact support@sophiagenetics.com to
obtain the appropriate product information for your country
of residence.
SOPHiA GENETICS Forward-Looking
Statements:
This press release contains statements
that constitute forward-looking statements. All statements other
than statements of historical facts contained in this press
release, including statements regarding our future results of
operations and financial position, business strategy, products, and
technology, as well as plans and objectives of management for
future operations, are forward-looking statements. Forward-looking
statements are based on our management's beliefs and assumptions
and on information currently available to our management. Such
statements are subject to risks and uncertainties, and actual
results may differ materially from those expressed or implied in
the forward-looking statements due to various factors, including
those described in our filings with the U.S. Securities and
Exchange Commission. No assurance can be given that such future
results will be achieved. Such forward-looking statements contained
in this press release speak only as of the date hereof. We
expressly disclaim any obligation or undertaking to update these
forward-looking statements contained in this press release to
reflect any change in our expectations or any change in events,
conditions, or circumstances on which such statements are based,
unless required to do so by applicable law. No representations or
warranties (expressed or implied) are made about the accuracy of
any such forward-looking statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/klinikum-klagenfurt-am-worthersee-is-live-with-sophia-genetics-302146026.html
SOURCE SOPHiA GENETICS